Editas Medicine
EDIT
199 hedge funds and large institutions have $1.06B invested in Editas Medicine in 2018 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 66 increasing their positions, 53 reducing their positions, and 42 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 53
20% more call options, than puts
Call options by funds: $25.2M | Put options by funds: $20.9M
1.61% more ownership
Funds ownership: 68.05% → 69.66% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 215 → 199 (-16)
8% less capital invested
Capital invested by funds: $1.15B → $1.06B (-$94.5M)
33% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$19.8M |
| 2 |
VCM
Valiant Capital Management
San Francisco,
California
|
+$12.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10.6M |
| 4 |
Renaissance Technologies
New York
|
+$9.7M |
| 5 |
CC
Casdin Capital
New York
|
+$9.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$44.3M |
| 2 |
Morgan Stanley
New York
|
-$10.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.09M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$4.91M |
| 5 |
PIMJS
PKO Investment Management Joint-Stock
Warsaw,
Poland
|
-$4.08M |
EDIT Hedge Fund Activity: Q3 2018 in Review
199 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2018, worth a combined $1.06B — down 8.2% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of EDIT and 28 opened new positions — a net loss of 14 holders — while 53 trimmed existing stakes and 66 added.
The largest buyer was ARK Investment Management, adding an estimated $19.8M. The largest seller was Fidelity Investments, cutting an estimated $44.3M.
- 199 institutional investors held Editas Medicine (EDIT) as of Q3 2018, down from 215 in Q2 2018.
- Funds reported $1.06B of Editas Medicine stock for Q3 2018, down 8.2% quarter-over-quarter.
- 28 funds opened new Editas Medicine positions in Q3 2018 and 42 closed out, a net change of -14 holders.
- The largest Editas Medicine buyer in Q3 2018 was ARK Investment Management, an estimated $19.8M added.
- The largest Editas Medicine seller in Q3 2018 was Fidelity Investments, an estimated $44.3M sold.
Based on aggregated 13F filings for Q3 2018.